2026 ICD-10-PCS Procedure Code XW033Q5

Introduction of Tagraxofusp-erzs Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5

ICD-10-PCS Code:: XW033Q5
ICD-10-PCS Code for:: Introduce Tagraxofusp-erzs in Periph Vein, Perc, New Tech 5
Is Billable?: Yes - Valid for Submission
Code Navigator:

XW033Q5 is a billable procedure code used to specify the performance of introduction of tagraxofusp-erzs antineoplastic into peripheral vein, percutaneous approach, new technology group 5. The code is valid for the year 2026 for the submission of HIPAA-covered transactions. The procedure code involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products.

Table of Contents

Code Information
PCS Table
Replacement Code
Other Similar Codes

XW033Q5 PCS Table

In an PCS table each code is represented by up seven alphanumeric characters, with each character in the table respresenting different aspects of the procedure. In the table provided below, each row represents an individual character and includes information about the character's position, designation, label, and procedure notes. For this PCS table the procedure code is in the new technology section and is part of the anatomical regions body system, classified under introduction operation. The applicable bodypart for this procedure code is peripheral vein.

Position	Designation	Character	Label	Procedures Notes
1	Section	X	New Technology
2	Body System	W	Anatomical Regions
3	Operation	0	Introduction	Involves: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
4	BodyPart	3	Peripheral Vein
5	Approach	3	Percutaneous	Involves: Entry, by puncture or minor incision, of instrumentation through the skin or mucous membrane and any other body layers necessary to reach the site of the procedure
6	Device/Substance/Technology	Q	Tagraxofusp-erzs Antineoplastic	Includes: ELZONRIS(tm)
7	Qualifier	5	New Technology Group 5

Replacement Code

XW033Q5 replaces the following previously assigned ICD-10-PCS code(s):

3E03305 - Introduce Oth Antineoplastic in Periph Vein, Perc
3E03305 - Introduce Oth Antineoplastic in Periph Vein, Perc
3E03305 - Introduce Oth Antineoplastic in Periph Vein, Perc
3E03305 - Introduce Oth Antineoplastic in Periph Vein, Perc
3E03305 - Introduce Oth Antineoplastic in Periph Vein, Perc
3E03305 - Introduce Oth Antineoplastic in Periph Vein, Perc
3E03305 - Introduce Oth Antineoplastic in Periph Vein, Perc

Other ICD-10-PCS Codes Used for Introduction Peripheral Vein

Filter related codes list:

XW03308 Introduction of Spesolimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW0333A Introduction of Bentracimab, Ticagrelor Reversal Agent into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW0334A Introduction of Cefepime-taniborbactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW03357 Introduction of Narsoplimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW03358 Introduction of Mosunetuzumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW0335A Introduction of Ceftobiprole Medocaril Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW03367 Introduction of Terlipressin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW03368 Introduction of Afamitresgene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW03372 Introduction of Inactivated Coagulation Factor Xa into Peripheral Vein, Percutaneous Approach, New Technology Group 2
XW03377 Introduction of Trilaciclib into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW03378 Introduction of Tabelecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW03387 Introduction of Lurbinectedin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW03388 Introduction of Treosulfan into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW0338A Introduction of Obecabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW03396 Introduction of Ceftolozane/Tazobactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW03398 Introduction of Inebilizumab-cdon into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW0339A Introduction of Odronextamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW033A7 Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033B3 Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 3
XW033B7 Introduction of Amivantamab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033BA Introduction of Orca-T Allogeneic T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW033C7 Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033CA Introduction of Zanidatamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW033DA Introduction of Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW033E5 Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033F3 Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 3
XW033F5 Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033FA Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW033FB Introduction of Valoctocogene Roxaparvovec-rvox into Peripheral Vein, Percutaneous Approach, New Technology Group 11
XW033G5 Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033G6 Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033G7 Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033H5 Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033H6 Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033H7 Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033J7 Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033K7 Introduction of Idecabtagene Vicleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033K9 Introduction of Sulbactam-Durlobactam into Peripheral Vein, Percutaneous Approach, New Technology Group 9
XW033L6 Introduction of CD24Fc Immunomodulator into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033L7 Introduction of Lifileucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033M7 Introduction of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033MA Introduction of Emapalumab-lzsg Anti-IFNy Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW033N7 Introduction of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033NA Introduction of Tarlatamab-dlle Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW033P9 Introduction of Glofitamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 9
XW033PB Introduction of Aztreonam-avibactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 11
XW033Q9 Introduction of Posoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 9
XW033QB Introduction of Iloprost into Peripheral Vein, Percutaneous Approach, New Technology Group 11
XW033R9 Introduction of Rezafungin into Peripheral Vein, Percutaneous Approach, New Technology Group 9
XW033RB Introduction of Letetresgene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 11
XW033S5 Introduction of Iobenguane I-131 Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033W5 Introduction of Caplacizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033WB Introduction of Fosfomycin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 11

What is ICD-10-PCS?

The ICD-10 Procedure Coding System (ICD-10-PCS) is a catalog of procedural codes used by medical professionals for hospital inpatient healthcare settings. The Centers for Medicare and Medicaid Services (CMS) maintain the catalog in the U.S. releasing yearly updates. The 2026 ICD-10-PCS codes are to be used for discharges occurring from October 1, 2025 through September 30, 2026.

Each ICD-10-PCS code has a structure of seven alphanumeric characters and contains no decimals. The first character defines the major "section". Depending on the "section" the second through seventh characters mean different things.